Every material Form 8-K InMed Pharmaceuticals Inc. has filed with the SEC since November 03, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
The merger between Mentari Therapeutics and InMed Pharmaceuticals closed on November 9, 2026, and the combined company now trades on the Nasdaq Capital Market as MTRI under the name Mentari Therapeutics, Inc. The closing included private placements with about $490 million in gross proceeds, which the company says provide runway into 2029, and the filing puts outstanding shares at about 58.3 million. The filing contains no revenue, profit, or guidance figures, so the financial effect on shareholders is defined mainly by the new capital and share count.
Private financings totaled about $490 million in gross proceeds, led by Fairmount, including conversion of $50.0 million of previously issued convertible notes plus accrued interest.
About 58.3 million shares of common stock and equivalents are outstanding after the reverse stock split, financings, and merger.
Shares began trading on Nasdaq Capital Market under the ticker MTRI on November 9, 2026.
Todd Shegog joined the Board and will chair the Audit Committee.
InMed Pharmaceuticals completed a 1-for-10 consolidation of its common shares and legally changed its name to Mentari Therapeutics, Inc., effective November 4, 2026, after shareholders approved all items at its annual general and special meeting. Shareholders approved the Nasdaq Share Issuance Proposal tied to the pending merger with Mentari, and the share count falls from about 5,493,735 to about 549,374, with trading under INM expected to resume on a post-consolidation basis on November 5, 2026.
Shareholders approved the Nasdaq Share Issuance Proposal with 97.295% of votes cast in favor (2,615,030 shares), covering shares to be issued in the merger with Mentari Therapeutics.
Consolidation: one post-consolidation common share for each ten pre-consolidation shares, reducing shares outstanding from 5,493,735 to about 549,374.
Common shares expected to trade on The Nasdaq Capital Market under INM from the start of trading on November 5, 2026, with new CUSIP 457637809.
One contingent value right per share is expected to be issued to holders of record at the close of business on November 5, 2026, under a CVR agreement to be entered into by the merger closing date.
InMed Pharmaceuticals, now named Mentari Therapeutics, Inc., reported that shareholders approved all ten proposals at its November 4, 2026 meeting, including a Nasdaq share issuance tied to the pending Mentari merger. The company also completed a 1-for-10 share consolidation, cutting common shares from 5,493,735 to about 549,374, and will trade under INM from November 5, 2026. The change lowers the share count and per-share figures, and creates Series A non-voting preferred shares that carry board-election and conversion terms.
Shareholders approved the Nasdaq share issuance for the Mentari merger with 2,615,030 votes for, 97.295% of votes cast.
Common shares were consolidated from 5,493,735 to about 549,374, with trading under INM expected from November 5, 2026 under new CUSIP 457637809.
4,013 preferred shares were designated as Series A Non-Voting Preferred, each convertible into 1,000 common shares, with a 19.99% ownership cap.
Shareholders approved redomestication from British Columbia to Nevada with 88.825% votes for; a CVR distribution record date of November 5, 2026 was set.
InMed Pharmaceuticals reported a first-quarter fiscal 2027 net loss of $2.3 million for the quarter ended September 30, 2026, up from $1.7 million a year earlier, and cash fell to $1.0 million from $2.2 million at June 30, 2026. The company said its cash is expected to fund operations into mid-November, and it reported shareholders' equity of negative $1.2 million, below Nasdaq's $2.5 million minimum, with a compliance deadline of March 15, 2027. Shareholders vote on the proposed Mentari merger at a meeting on November 4, 2026.
Net loss of $2.3 million, or $0.42 per share, for the quarter ended September 30, 2026, compared with a net loss of $1.7 million, or $0.44 per share, a year earlier
Cash and cash equivalents of $1.0 million at September 30, 2026, versus $2.2 million at June 30, 2026; cash expected to fund operations into mid-November
Shareholders' equity was negative $1.2 million at September 30, 2026; Nasdaq set a March 15, 2027 deadline to regain compliance with its $2.5 million minimum
Annual general and special meeting on November 4, 2026, to consider proposals needed to complete the Mentari merger, which is expected to close in the fourth quarter of calendar 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every InMed Pharmaceuticals Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →